"The first phase of polling had marked the end of the TMC's 'maha jungle raj'," he claimed. Prime Minister Narendra Modi on Friday claimed that the "wave of change" in West Bengal has become evident ...

EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...

The Loop Dallas, when it is completed next year, will create a 50-mile paved trail system that joins 39 miles of existing trails with 11 new ones. On Tuesday, officials and representatives from Dallas ...

Forbes contributors publish independent expert analyses and insights. author of Chained to the Desk in a Hybrid World: A Guide to Balance. Who says you can’t find work that also allows you to have fun ...

Construction mobilisation has begun for the Dubai Loop, with Elon Musk’s The Boring Company saying the first step is to activate precast concrete segment production for the project. The development ...

Efficacy of erdafitinib in adults with advanced solid tumors and non-prespecified fibroblast growth factor receptor mutations in the phase 2 RAGNAR trial: Exploratory cohort. This is an ASCO Meeting ...

KOLKATA: SIR may have knocked out lakhs of Bengal voters, but the crores who have stayed on the roll have sent out an unmistakable signal on how important they consider their voting rights to be.An ...

West Bengal Assembly Elections 2026 Phase 1 Voting Highlights: West Bengal voted today in the first phase of the assembly elections, with polling being held in 152 constituencies across north Bengal ...

Forbes contributors publish independent expert analyses and insights. I write about relationships, personality, and everyday psychology. The initial months of a relationship, often referred to as the ...

Supply chains are messy. San Francisco-based startup Loop isn’t content helping companies merely clean up their supply chains. Instead, the startup is using AI to offer companies predictive, and even ...

More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody, which suggests the drug boasts similar safety and efficacy in non ...